Go Pro
→ This tiny piece of glass could be bigger than GPUs (From Brownstone Research) (Ad)tc pixel Free CMPX Stock Alerts

Compass Therapeutics (CMPX) Financials

Compass Therapeutics logo
$2.07 -0.05 (-2.36%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$2.08 +0.02 (+0.72%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Compass Therapeutics

Annual Income Statements for Compass Therapeutics

This table shows Compass Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -35 -30 -82 -39 -42 -49 -66
Consolidated Net Income / (Loss)		 -35 -30 -82 -39 -42 -49 -66
Net Income / (Loss) Continuing Operations		 -35 -30 -82 -39 -42 -49 -66
Total Pre-Tax Income 		-35 -29 -82 -39 -42 -49 -66
Total Operating Income		 -34 -28 -82 -42 -50 -57 -73
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.85 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.85 0.00
Operating Revenue		 - - - - 0.00 0.85 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 34 28 82 42 50 57 73
Selling, General & Admin Expense		 12 13 11 12 12 15 17
Research & Development Expense		 22 15 71 30 38 42 56
Total Other Income / (Expense), net		 -0.60 -1.66 -0.30 2.43 7.87 7.25 6.35
Other Income / (Expense), net		 0.63 -1.66 -0.30 2.43 7.87 7.25 6.35
Basic Earnings per Share		 ($5.19) ($0.96) ($1.31) ($0.37) ($0.33) ($0.36) ($0.42)
Weighted Average Basic Shares Outstanding		 6.69M 30.78M 62.87M 105.19M 127.03M 137.38M 157.70M
Weighted Average Diluted Shares Outstanding		 6.69M 30.78M 62.87M 126.51M 137.59M 138.28M 180.09M
Weighted Average Basic & Diluted Shares Outstanding		 6.69M 30.78M 62.87M 126.51M 137.59M 138.28M 180.09M

Quarterly Income Statements for Compass Therapeutics

This table shows Compass Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -9.96 -13 -11 -13 -10 -15 -17 -20 -14 -16 -18
Consolidated Net Income / (Loss)		 -9.96 -13 -11 -13 -10 -15 -17 -20 -14 -16 -18
Net Income / (Loss) Continuing Operations		 -9.96 -13 -11 -13 -10 -15 -17 -20 -14 -16 -18
Total Pre-Tax Income 		-9.96 -13 -11 -13 -10 -15 -17 -20 -14 -16 -18
Total Operating Income		 -12 -15 -13 -15 -12 -17 -18 -21 -16 -18 -20
Total Gross Profit		 0.00 - 0.00 0.85 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.85 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 12 15 13 16 12 17 18 21 16 18 20
Selling, General & Admin Expense		 3.10 2.96 3.25 4.72 3.63 3.54 4.91 4.65 2.99 4.32 6.91
Research & Development Expense		 8.83 12 9.52 11 8.61 13 13 16 13 14 13
Total Other Income / (Expense), net		 1.96 1.97 1.98 1.97 1.76 1.54 1.33 1.19 1.56 2.27 1.98
Other Income / (Expense), net		 1.96 1.97 1.98 1.97 1.76 1.54 1.33 1.19 1.56 2.27 1.98
Basic Earnings per Share		 ($0.08) ($0.10) ($0.08) ($0.10) ($0.08) ($0.10) ($0.12) ($0.14) ($0.08) ($0.08) ($0.10)
Weighted Average Basic Shares Outstanding		 127.42M 127.03M 136.61M 137.59M 137.59M 137.38M 138.24M 138.28M 168.78M 157.70M 186.40M
Weighted Average Diluted Shares Outstanding		 127.49M 137.59M 137.59M 137.59M 137.59M 138.28M 138.28M 138.28M 177.86M 180.09M 180.09M
Weighted Average Basic & Diluted Shares Outstanding		 127.49M 137.59M 137.59M 137.59M 137.59M 138.28M 138.28M 138.28M 177.86M 180.09M 180.09M

Annual Cash Flow Statements for Compass Therapeutics

This table details how cash moves in and out of Compass Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -32 22 97 -110 -11 19 -13
Net Cash From Operating Activities		 -32 -27 -20 -34 -41 -45 -49
Net Cash From Continuing Operating Activities		 -32 -27 -20 -34 -41 -45 -49
Net Income / (Loss) Continuing Operations		 -35 -30 -82 -39 -42 -49 -66
Consolidated Net Income / (Loss)		 -35 -30 -82 -39 -42 -49 -66
Depreciation Expense		 2.12 2.40 0.57 0.78 0.70 0.59 0.28
Amortization Expense		 - 0.00 1.06 0.32 -2.04 -0.49 -0.48
Non-Cash Adjustments To Reconcile Net Income		 1.14 4.94 54 4.16 4.92 7.34 8.00
Changes in Operating Assets and Liabilities, net		 -0.25 -4.65 7.36 -0.16 -1.71 -2.93 9.55
Net Cash From Investing Activities		 -0.47 0.04 -1.77 -151 27 47 -93
Net Cash From Continuing Investing Activities		 -0.47 0.04 -1.77 -151 27 47 -93
Purchase of Property, Plant & Equipment		 -0.47 -0.11 -1.57 -0.21 -0.03 -0.04 -0.03
Purchase of Investments		 - - 0.00 -200 -155 -88 -195
Sale and/or Maturity of Investments		 - - 0.00 49 182 135 101
Net Cash From Financing Activities		 0.00 49 119 76 2.94 17 130
Net Cash From Continuing Financing Activities		 0.00 49 119 76 2.94 17 130
Repurchase of Common Equity		 0.00 -6.32 -0.28 -0.50 -0.09 -0.54 -8.64
Issuance of Common Equity		 0.00 60 128 76 3.13 18 138
Other Financing Activities, net		 - - 0.00 0.02 -0.10 -0.23 0.25

Quarterly Cash Flow Statements for Compass Therapeutics

This table details how cash moves in and out of Compass Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 11 -6.20 -0.55 -4.27 18 6.11 -2.44 -18 23 -16 25
Net Cash From Operating Activities		 -5.92 -12 -14 -11 -11 -9.16 -13 -12 -11 -13 -17
Net Cash From Continuing Operating Activities		 -5.92 -12 -14 -11 -11 -9.16 -13 -12 -11 -13 -17
Net Income / (Loss) Continuing Operations		 -9.96 -13 -11 -13 -10 -15 -17 -20 -14 -16 -18
Consolidated Net Income / (Loss)		 -9.96 -13 -11 -13 -10 -15 -17 -20 -14 -16 -18
Depreciation Expense		 0.16 0.16 0.15 0.15 0.14 0.14 0.14 0.10 0.02 0.02 0.02
Amortization Expense		 -0.48 -0.51 -0.07 -0.41 0.04 -0.05 0.22 0.14 -0.02 -0.84 0.15
Non-Cash Adjustments To Reconcile Net Income		 1.32 1.29 1.68 1.80 2.20 1.66 2.49 2.75 1.20 1.79 5.04
Changes in Operating Assets and Liabilities, net		 3.04 0.12 -4.87 0.79 -2.96 4.12 0.52 5.06 2.21 1.50 -4.15
Net Cash From Investing Activities		 17 6.31 -4.10 6.48 29 15 12 -6.36 -95 -3.38 38
Net Cash From Continuing Investing Activities		 17 6.31 -4.10 6.48 29 15 12 -6.36 -95 -3.38 38
Purchase of Property, Plant & Equipment		 -0.01 -0.01 0.00 - -0.04 - -0.02 - -0.01 - -0.08
Purchase of Investments		 -17 -45 -42 -31 -5.35 -9.86 -25 -33 -109 -27 -45
Sale and/or Maturity of Investments		 34 51 38 38 34 25 36 27 14 24 83
Net Cash From Financing Activities		 0.02 -0.16 17 0.00 -0.00 -0.09 -0.82 - 129 1.06 3.37
Net Cash From Continuing Financing Activities		 0.02 -0.16 17 0.00 -0.00 -0.09 -0.82 - 129 1.06 3.37
Other Financing Activities, net		 0.02 -0.16 -0.14 - - -0.10 -0.82 - - 1.06 3.37

Annual Balance Sheets for Compass Therapeutics

This table presents Compass Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2018 3/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.00 0.00 52 154 200 157 140 220
Total Current Assets		 0.00 0.00 50 147 195 154 133 210
Cash & Equivalents		 0.00 0.00 47 145 35 24 43 31
Restricted Cash		 - - - - - - 0.57 0.57
Short-Term Investments		 - - - 0.00 152 128 83 178
Prepaid Expenses		 - - 3.13 2.59 8.18 1.42 6.03 0.91
Plant, Property, & Equipment, net		 0.00 0.00 1.13 2.24 1.57 0.90 0.35 0.10
Total Noncurrent Assets		 0.00 0.00 0.58 4.41 3.29 2.10 6.73 9.10
Other Noncurrent Operating Assets		 - - 0.58 4.41 3.29 2.10 6.73 9.10
Total Liabilities & Shareholders' Equity		 0.00 0.00 52 154 200 157 140 220
Total Liabilities		 0.03 0.08 12 14 18 8.34 15 23
Total Current Liabilities		 0.03 0.08 10 11 16 7.80 8.87 14
Accounts Payable		 0.00 0.00 1.06 0.87 3.38 4.09 2.25 1.59
Accrued Expenses		 - - 1.57 8.78 12 2.51 6.29 11
Other Current Liabilities		 - - 0.00 0.99 1.10 - 0.34 1.00
Total Noncurrent Liabilities		 0.00 0.00 1.87 3.05 1.84 0.54 6.30 8.83
Other Noncurrent Operating Liabilities		 - - 0.00 3.05 1.84 0.54 6.30 8.83
Commitments & Contingencies		 - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -0.03 -0.07 40 140 182 149 125 197
Total Preferred & Common Equity		 -0.03 -0.07 40 140 182 149 125 197
Total Common Equity		 -0.03 -0.07 40 140 182 149 125 197
Common Stock		 0.00 0.00 191 374 455 464 490 628
Retained Earnings		 -0.04 -0.07 -151 -234 -273 -315 -365 -431
Accumulated Other Comprehensive Income / (Loss)		 - - - 0.00 -0.30 0.04 0.21 0.28

Quarterly Balance Sheets for Compass Therapeutics

This table presents Compass Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 179 170 161 156 149 131 117 231 205
Total Current Assets		 175 167 159 154 141 124 106 221 196
Cash & Equivalents		 19 30 24 19 37 41 23 46 55
Restricted Cash		 - - - - - 0.57 0.57 0.57 0.57
Short-Term Investments		 149 133 133 127 99 72 78 174 140
Prepaid Expenses		 6.52 2.88 2.36 7.32 5.74 12 5.25 1.23 1.00
Plant, Property, & Equipment, net		 1.20 1.05 0.74 0.59 0.49 0.23 0.13 0.12 0.17
Total Noncurrent Assets		 2.71 2.40 1.79 1.47 7.52 6.51 9.80 9.45 8.75
Other Noncurrent Operating Assets		 2.71 2.40 1.79 1.47 7.52 6.51 9.80 9.45 8.75
Total Liabilities & Shareholders' Equity		 179 170 161 156 149 131 117 231 205
Total Liabilities		 11 9.99 4.08 9.51 11 21 23 22 19
Total Current Liabilities		 9.70 9.12 3.89 9.51 4.43 15 14 12 10
Accounts Payable		 0.72 2.31 0.85 1.19 0.96 1.58 2.60 3.10 0.91
Accrued Expenses		 7.83 5.64 1.82 7.23 2.92 13 11 8.68 8.00
Other Current Liabilities		 - - - - 0.56 0.11 0.27 0.63 1.37
Total Noncurrent Liabilities		 1.20 0.87 0.19 0.00 6.32 6.27 9.63 9.23 8.42
Other Noncurrent Operating Liabilities		 1.20 0.87 0.19 0.00 6.32 6.27 9.63 9.23 8.42
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 168 160 157 146 138 110 93 210 186
Total Preferred & Common Equity		 168 160 157 146 138 110 93 210 186
Total Common Equity		 168 160 157 146 138 110 93 210 186
Common Stock		 461 462 483 485 488 491 494 625 636
Retained Earnings		 -292 -302 -326 -339 -350 -381 -401 -415 -449
Accumulated Other Comprehensive Income / (Loss)		 -0.51 -0.43 -0.09 -0.09 0.49 0.19 0.21 0.27 -0.16

Annual Metrics And Ratios for Compass Therapeutics

This table displays calculated financial ratios and metrics derived from Compass Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 5,000,000.00 52,123,374.00 98,031,565.00 126,191,473.00 127,486,326.00 - 177,862,102.00
DEI Adjusted Shares Outstanding		 5,000,000.00 52,123,374.00 98,031,565.00 126,191,473.00 127,486,326.00 - 177,862,102.00
DEI Earnings Per Adjusted Shares Outstanding		 -6.95 -0.57 -0.84 -0.31 -0.33 - -0.37
Growth Metrics		 - - - - - - -
Profitability Metrics		 - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -24 -19 -57 -29 -35 -40 -51
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -23.54% -31.57% -25.91%
Earnings before Interest and Taxes (EBIT)		 -33 -29 -82 -39 -42 -49 -66
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -31 -27 -81 -38 -44 -49 -67
Valuation Ratios		 - - - - - - -
Leverage & Solvency		 - - - - - - -
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -22 -51 -29 -37 -41 -40
Efficiency Ratios		 - - - - - - -
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -0.00 2.20 -4.44 -4.97 -2.73 -1.15 -13
Increase / (Decrease) in Invested Capital		 0.00 2.21 -6.64 -0.54 2.25 1.58 -11
Book Value per Share		 ($0.01) $0.77 $1.43 $1.44 $1.17 $0.91 $1.11
Tangible Book Value per Share		 ($0.01) $0.77 $1.43 $1.44 $1.17 $0.91 $1.11
Total Capital		 0.00 49 140 182 150 126 197
Total Debt		 0.07 9.33 0.00 0.00 1.20 0.34 0.00
Total Long-Term Debt		 0.00 1.87 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.07 -38 -145 -187 -151 -126 -209
Capital Expenditures (CapEx)		 0.47 -0.04 1.45 0.04 0.03 0.04 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.00 0.49 -8.04 -7.99 -5.18 -2.51 -14
Debt-free Net Working Capital (DFNWC)		 0.00 48 136 179 147 124 196
Net Working Capital (NWC)		 -0.07 40 136 179 146 124 196
Net Nonoperating Expense (NNE)		 11 10 25 10 7.24 9.74 16
Net Nonoperating Obligations (NNO)		 0.07 -38 -145 -187 -151 -126 -209
Total Depreciation and Amortization (D&A)		 2.12 2.40 1.62 1.10 -1.34 0.10 -0.20
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 ($0.01) $0.00 ($1.31) ($0.37) ($0.33) ($0.36) ($0.42)
Adjusted Weighted Average Basic Shares Outstanding		 5M 0.00 101.30M 105.19M 127.03M 137.38M 157.70M
Adjusted Diluted Earnings per Share		 ($0.01) $0.00 ($1.31) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 5M 0.00 101.30M 126.51M 137.59M 138.28M 180.09M
Adjusted Basic & Diluted Earnings per Share		 ($0.01) $0.00 ($1.31) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5M 0.00 62.87M 126.51M 137.59M 138.28M 180.09M
Normalized Net Operating Profit after Tax (NOPAT)		 -24 -19 -57 -29 -35 -40 -51
Debt Service Ratios		 - - - - - - -
Payout Ratios		 - - - - - - -

Quarterly Metrics And Ratios for Compass Therapeutics

This table displays calculated financial ratios and metrics derived from Compass Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 127,459,346.00 127,486,326.00 137,589,171.00 137,589,171.00 137,589,171.00 - 138,282,498.00 138,282,498.00 138,282,498.00 177,862,102.00 180,087,915.00
DEI Adjusted Shares Outstanding		 127,459,346.00 127,486,326.00 137,589,171.00 137,589,171.00 137,589,171.00 - 138,282,498.00 138,282,498.00 138,282,498.00 177,862,102.00 180,087,915.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.08 -0.11 -0.08 -0.10 -0.08 - -0.12 -0.14 -0.10 -0.09 -0.10
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% - 0.00%
EBITDA Growth		 12.76% -17.39% -34.61% -12.66% -0.10% -8.60% -51.80% -47.27% -38.56% - -11.59%
EBIT Growth		 16.79% -15.71% -37.64% -15.94% -5.19% -12.05% -54.19% -52.04% -36.05% - -10.12%
NOPAT Growth		 5.33% -19.41% -31.50% -12.81% -2.62% -7.68% -40.69% -40.02% -29.23% - -12.99%
Net Income Growth		 16.79% -15.71% -37.64% -15.94% -5.19% -12.05% -54.19% -52.04% -36.05% - -10.12%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Cash Flow Growth		 45.88% -16.10% -13.57% -6.34% -86.61% 25.84% 4.90% -10.02% 1.83% - -30.75%
Free Cash Flow Firm Growth		 -368.42% -53.39% -23.81% 23.05% -35.72% -1.21% 29.89% 49.41% 119.75% - -9.55%
Invested Capital Growth		 44.63% 45.16% 2,035.79% 41.70% 220.61% 57.78% -244.11% -961.14% -462.15% - -200.34%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Q/Q Growth		 13.13% -33.79% 22.23% -24.64% 22.82% -45.15% -8.71% -20.93% 27.39% - -9.75%
EBIT Q/Q Growth		 11.65% -34.63% 19.59% -21.22% 19.85% -43.41% -10.66% -19.53% 28.28% - -16.55%
NOPAT Q/Q Growth		 10.58% -29.04% 17.02% -17.82% 18.65% -35.40% -8.42% -17.25% 24.92% - -12.83%
Net Income Q/Q Growth		 11.65% -34.63% 19.59% -21.22% 19.85% -43.41% -10.66% -19.53% 28.28% - -16.55%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Cash Flow Q/Q Growth		 41.44% -108.61% -12.42% 22.57% -2.76% 17.09% -44.16% 10.42% 8.31% - -30.29%
Free Cash Flow Firm Q/Q Growth		 26.36% -25.77% 16.47% 0.53% -29.88% 6.21% 42.14% 28.23% 150.70% - -324.57%
Invested Capital Q/Q Growth		 -464.76% -9.74% 174.43% -52.44% 210.47% -138.42% -154.04% -184.20% -30.57% - 30.76%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% -1,569.06% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Margin		 0.00% 0.00% 0.00% -1,770.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBIT Margin		 0.00% 0.00% 0.00% -1,538.35% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -1,538.35% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -1,279.65% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -1,278.02% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 1,271.33% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -29.46% -25.74% -27.35% -8.32% 0.00% -36.07% -41.31% -51.84% -37.82% - -45.95%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -3,703.33% -4,723.57% -1,478.31% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -7.81% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -7.81% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 -29.46% -25.74% -27.35% -8.32% 0.00% -36.07% -41.31% -51.84% -37.82% - -45.95%
Return on Equity Simple (ROE_SIMPLE)		 -25.41% 0.00% -28.93% 0.00% 0.00% 0.00% -50.07% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.35 -11 -8.94 -11 -8.57 -12 -13 -15 -11 -13 -14
NOPAT Margin		 0.00% 0.00% 0.00% -1,239.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.14% -1.56% -1.12% -1.63% -1.28% -2.47% -3.02% -4.16% -1.79% - -2.66%
Return On Investment Capital (ROIC_SIMPLE)		 - -7.19% -5.65% -7.15% -6.19% -9.24% -11.40% -15.82% -5.28% -6.40% -7.62%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 555.41% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 1,314.59% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 1,870.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -9.96 -13 -11 -13 -10 -15 -17 -20 -14 -16 -18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -10 -14 -11 -13 -10 -15 -16 -20 -14 -17 -18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.57 1.34 1.73 0.94 1.83 1.59 2.38 3.86 2.31 - 5.11
Price to Tangible Book Value (P/TBV)		 1.57 1.34 1.73 0.94 1.83 1.59 2.38 3.86 2.31 - 5.11
Price to Revenue (P/Rev)		 0.00 0.00 0.00 161.87 297.84 234.71 309.10 0.00 0.00 - 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 57.86 0.00 39.31 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 138.54 86.02 175.92 0.00 0.00 - 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -1.03 -1.02 -0.99 -0.99 -1.00 -1.01 -1.00 -1.03 -1.02 - -1.04
Leverage Ratio		 1.08 1.08 1.05 1.06 1.07 1.09 1.09 1.14 1.09 - 1.13
Compound Leverage Factor		 1.08 1.08 1.05 1.06 1.07 1.09 1.09 1.14 1.09 - 1.13
Debt to Total Capital		 0.73% 0.80% 0.77% 0.74% 0.00% 0.27% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.73% 0.80% 0.77% 0.74% 0.00% 0.27% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 99.27% 99.20% 99.23% 99.26% 100.00% 99.73% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 -0.03 -0.03 -0.03 -0.02 0.00 -0.01 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 3.89 3.45 3.33 3.02 0.00 2.57 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 -0.04 -0.03 -0.03 -0.03 0.00 -0.01 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 4.85 4.29 4.15 3.76 0.00 3.19 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 13.51 12.33 38.14 6.47 11.72 4.97 3.97 4.76 11.78 - 28.29
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 18.26 19.73 40.74 16.15 31.84 14.96 8.33 7.66 17.82 - 19.04
Quick Ratio		 17.94 19.54 40.14 15.38 30.54 14.28 7.56 7.28 17.72 - 18.94
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -10 -13 -11 -11 -14 -13 -7.62 -5.47 2.77 -1.97 -8.35
Operating Cash Flow to CapEx		 -59,220.00% -137,266.67% 0.00% 0.00% -25,115.91% 0.00% -73,377.78% 0.00% -154,985.71% - -21,059.76%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.00 - 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.95 1.10 1.36 1.74 0.00 0.00 - 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.48 -2.73 2.03 0.97 3.00 -1.15 -2.92 -8.31 -11 -13 -8.78
Invested Capital Turnover		 0.00 0.00 0.00 1.03 3.32 -0.44 -1.90 0.00 0.00 - 0.00
Increase / (Decrease) in Invested Capital		 2.00 2.25 1.93 0.28 5.48 1.58 -4.95 -9.28 -14 -11 -5.86
Enterprise Value (EV)		 89 48 117 -7.55 118 73 150 258 264 - 757
Market Capitalization		 251 199 272 138 253 200 263 360 484 - 953
Book Value per Share		 $1.26 $1.17 $1.14 $1.06 $1.01 $0.91 $0.80 $0.67 $1.52 $1.11 $1.04
Tangible Book Value per Share		 $1.26 $1.17 $1.14 $1.06 $1.01 $0.91 $0.80 $0.67 $1.52 $1.11 $1.04
Total Capital		 161 150 158 147 138 126 110 93 210 197 186
Total Debt		 1.17 1.20 1.22 1.09 0.00 0.34 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -163 -151 -155 -145 -135 -126 -113 -102 -220 -209 -195
Capital Expenditures (CapEx)		 0.01 0.01 0.00 0.00 0.04 0.00 0.02 0.00 0.01 0.00 0.08
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.07 -5.18 -0.31 -1.10 1.31 -2.51 -3.96 -9.18 -12 -14 -9.85
Debt-free Net Working Capital (DFNWC)		 159 147 156 145 137 124 109 92 209 196 185
Net Working Capital (NWC)		 157 146 155 144 137 124 109 92 209 196 185
Net Nonoperating Expense (NNE)		 1.62 2.64 1.85 2.54 1.91 3.43 4.06 5.13 3.19 3.12 4.11
Net Nonoperating Obligations (NNO)		 -163 -151 -155 -145 -135 -126 -113 -102 -220 -209 -195
Total Depreciation and Amortization (D&A)		 -0.32 -0.34 0.09 -0.26 0.19 0.09 0.39 0.24 -0.00 -0.83 0.16
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -129.41% 153.53% -294.94% -465.65% 0.00% 0.00% - 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 17,073.76% 16,083.18% 14,613.53% 12,852.35% 0.00% 0.00% - 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 16,945.76% 16,083.18% 14,573.76% 12,852.35% 0.00% 0.00% - 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.08) ($0.10) ($0.08) ($0.10) ($0.08) ($0.10) ($0.12) ($0.14) ($0.08) ($0.08) ($0.10)
Adjusted Weighted Average Basic Shares Outstanding		 127.42M 127.03M 136.61M 137.59M 137.59M 137.38M 138.24M 138.28M 168.78M 157.70M 186.40M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 127.49M 137.59M 137.59M 137.59M 137.59M 138.28M 138.28M 138.28M 177.86M 180.09M 180.09M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 127.49M 137.59M 137.59M 137.59M 137.59M 138.28M 138.28M 138.28M 177.86M 180.09M 180.09M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.35 -11 -8.94 -11 -8.57 -12 -13 -15 -11 -13 -14
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -1,239.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -1,538.35% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 -1.45% -0.22% -1.40% -1.15% -1.14% -1.10% 0.00% 0.00% -13.12% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Compass Therapeutics (NASDAQ: CMPX) remains a pre-revenue biotech with no operating revenue across the last four years of reported quarters. The company continues to post quarterly losses, but its cash position and investment portfolio have been substantial enough to support operations. The most recent quarter shows a modest worsening in losses and cash burn versus the prior quarter, while the balance sheet still looks liquid.

  • Compass ended Q3 2025 with $220.4 million in current assets, including $46.2 million in cash and $173.7 million in short-term investments, giving it a sizable liquidity cushion.
  • Total equity improved to $209.6 million in Q3 2025 from $93.2 million in Q2 2025, helped by the company’s large equity issuance and stronger cash/investment balances.
  • The company generated net cash from investing activities of $11.6 million in Q1 2025 and $12.9 million from financing in Q3 2025, showing it can raise and redeploy capital when needed.
  • Other income has consistently helped offset operating losses, ranging from roughly $1.2 million to $2.3 million in recent quarters, mainly likely tied to interest or investment income.
  • Net income per share remained relatively stable at around $(0.08) to $(0.14) per share in 2025 quarters, though this is not a sign of profitability because the business still lacks revenue.
  • Q4 2025 net loss widened to $15.7 million from $14.3 million in Q3 2025 and $15.0 million in Q4 2024, indicating losses remain persistent.
  • Operating cash flow stayed negative, with Q4 2025 operating cash burn of $13.3 million and Q3 2025 burn of $10.8 million.
  • The company reported no revenue in every quarter shown from 2023 through 2025, so the business is still entirely dependent on financing and investment income.
  • Research and development spending remains the largest expense category, running $12.8 million to $16.4 million per quarter in 2025, which is typical for biotech but keeps losses elevated.
  • Cash and equivalents declined to $46.2 million in Q3 2025 from $228.6 million in Q2 2025, reflecting major investment activity and financing changes rather than operating improvement.

Looking at the broader trend, Compass Therapeutics has steadily burned cash from operations over the past several years, while relying on investments and occasional equity financing to maintain its balance sheet. The company’s liquidity remains strong for now, but the absence of revenue means investors are still underwriting clinical progress, not a self-sustaining business model.

Bottom line: CMPX has a healthy cash and investment position, but the financial statements still show a company in development mode with ongoing losses, negative operating cash flow, and no revenue base. The stock’s long-term case will likely depend on clinical and pipeline execution rather than current fundamentals.

07/26/26 11:34 PM ETAI Generated. May Contain Errors.

Compass Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Compass Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Compass Therapeutics' net income appears to be on an upward trend, with a most recent value of -$66.49 million in 2025, rising from -$34.74 million in 2019. The previous period was -$49.38 million in 2024. See where experts think Compass Therapeutics is headed by visiting Compass Therapeutics' forecast page.

Compass Therapeutics' total operating income in 2025 was -$72.84 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $72.84 million

Over the last 6 years, Compass Therapeutics' total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Compass Therapeutics' total liabilities were at $22.80 million at the end of 2025, a 50.3% increase from 2024, and a 65,831.1% increase since 2018.

In the past 7 years, Compass Therapeutics' cash and equivalents has ranged from $0.00 in 2018 to $144.51 million in 2021, and is currently $30.64 million as of their latest financial filing in 2025.

Over the last 6 years, Compass Therapeutics' book value per share changed from -0.01 in 2019 to 1.11 in 2025, a change of -7,946.8%.


Related Companies

Financial statements for NASDAQ:CMPX last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Universal basic income is not impossible. It exist (kind of)
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
BlackRock's $2.8B Clue (most investors missed)
BlackRock's new fund on the emerging financial grid hit 2.8 billion in assets in just three months, according ...
Awesomely | Sponsoredtc pixel
Oxford Club Analyst’s Urgent AI Warning
Alexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...
The Oxford Club | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
August 6 could be a BIG day for one AI company
One AI company's revenue has surged 757 percent in the past year, earning it an A rating from Louis Navellier'...
InvestorPlace | Sponsoredtc pixel
The invention Elon called the greatest in history
Jeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...
Brownstone Research | Sponsoredtc pixel